Presentation is loading. Please wait.

Presentation is loading. Please wait.

Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression.

Published bySilvia Castilla Zúñiga Modified over 5 years ago

Similar presentations

Presentation on theme: "Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression."— Presentation transcript:

1 Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression. Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression. Expression of SUFU and GLI1 was confirmed by real-time PCR using primary B-CLL cells from 38 patients. There was a significant increase in SUFU and GLI1 expression in the poor clinical outcome subgroup (low normalized Ct value) compared with good clinical outcome subgroup (high normalized Ct value) based on either cytogenetics (n = 38; A and B) or CD38 expression (n = 34; C and D). E to H. Expression of SUFU and GLI1 by real-time PCR and GLI2 and BCL2 by microarray analysis correlated with time to treatment in Kaplan-Meier analysis. Expression of Hh signaling molecules, such as SUFU, GLI1, GLI2, and BCL2, was significantly correlated with disease progression. Ganapati V. Hegde et al. Mol Cancer Res 2008;6: ©2008 by American Association for Cancer Research

Download ppt "Overexpression of SUFU and GLI1 in the poor clinical outcome subgroup was confirmed by real-time PCR along with its association with disease progression."

Similar presentations

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.

C1q g/L C2 g/L C3 g/L C4 g/L A. B. C.D. E. Supplementary Figure 1 - Middleton et al. NR Supplementary Figure 1. Complement concentrations in CLL patient.
PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.

PIK3CA gene amplification in glioblastoma and squamous cell carcinoma (SCC) of the lung. PIK3CA gene amplification in glioblastoma and squamous cell carcinoma.
The expression and signaling of FGFR3 in WM cells.

The expression and signaling of FGFR3 in WM cells.
VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome.
CD25 expression is associated with unfavorable clinical outcome.

CD25 expression is associated with unfavorable clinical outcome.
Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.

Correlation of log-transformed signal intensity from two Affymetrix microarray hybridizations using platelet RNA. Plotted are those probesets with an average.
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 The association between CD8+ T‑cell density of the tumour
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
CHK1 downregulation upon ERG overexpression.

CHK1 downregulation upon ERG overexpression.
Enrollment and Outcomes

Enrollment and Outcomes
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:1578-88.

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.
Increased expression levels of CHIT1 in the patients with IPF where they correlate inversely with SMAD7. Increased expression levels of CHIT1 in the patients.

Increased expression levels of CHIT1 in the patients with IPF where they correlate inversely with SMAD7. Increased expression levels of CHIT1 in the patients.
SIRT1 is downregulated in human gastric cancer (GC).

SIRT1 is downregulated in human gastric cancer (GC).
Sufu is required for the stabilization of Gli2 and Gli3 proteins in vivo. Sufu is required for the stabilization of Gli2 and Gli3 proteins in vivo. (A)

Sufu is required for the stabilization of Gli2 and Gli3 proteins in vivo. Sufu is required for the stabilization of Gli2 and Gli3 proteins in vivo. (A)
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.

A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.
NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.

NAPRT expression correlates to sensitivity for NAMPT inhibitors and to methylation of the CpG island of the NAPRT promoter. NAPRT expression correlates.
Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Activating mutation of Ras is associated with CDCP1 expression in NSCLC. A, NSCLC cell lines with Ras + B-Raf mutations and wild-type Ras were examined.

Similar presentations

Ads by Google